Dr Stephen Shuttleworth, FRSC, CChem

Stephen is the Chairman of Karus’s Scientific Advisory Board and is the founding scientist of the Company’s PI3K-p110β/δ and HDAC6 programs. He is an Entrepreneur-in-Residence at Samsara BioCapital, California, and a Non-Executive Director at Hox Therapeutics, UK

Previously, he was the company’s CSO, an Executive Director (2008-2019) and COO (2017-2019). Before that, Stephen held R&D leadership positions in UK and North American biotech, working in several disease areas across multiple therapeutic targets, notably at Chiroscience, BiochemPharma, Tularik, Piramed (2003-2006), and CRUK (2006-2008). At Piramed, he directed the PI3K programs, designing and leading the preclinical development of Pictilisib, partnered with Genentech and subsequently taken into Phase II by Roche, who acquired Piramed for $160 million in 2008.

Stephen obtained his BSc and PhD in Chemistry from the University of Liverpool, has published extensively, and has been an invited speaker at international conferences. In 2007 he was appointed a Fellow of the Royal Society of Chemistry, and in 2014 an Honorary Professor (Molecular & Clinical Cancer Sciences, School of Medical Science) at the University of Manchester.